Podcasts about phase ii

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-468

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-468

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Show Notes: https://securityweekly.com/esw-468

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Show Notes: https://securityweekly.com/esw-468

Pentagon suspends CMMC Phase II requirements US troop location data under attack in Iran "Context Bombing" flips the script on prompt injections Get the show notes here: https://cisoseries.com/cybersecurity-news-cmmc-phase-ii-suspended-tracking-troops-in-iran-defenders-turn-to-context-bombing/  Huge thanks to our sponsor, ThreatLocker Every security leader is being asked the same question right now: How do we enable innovation without creating unnecessary risk? That's the challenge behind cloud adoption. Behind AI. Behind automation. And behind every major technology decision. ThreatLocker helps organizations take a Zero Trust approach to that challenge—giving them greater control over what can execute, what can access their environment, and what users and applications are allowed to do. That's why ThreatLocker is proud to support Cyber Security Headlines. Because security works best when innovation and control move together.

This week on the Midweek Takeaway, Kevin Hornsby is joined by Jeremy Skillington and Cathal Friel from Poolbeg Pharma to discuss the company's latest clinical milestone after dosing the first patient in its Phase II trial for POLB 001.The discussion covers how the treatment is designed to prevent cytokine release syndrome (CRS) in patients receiving cancer immunotherapies, the significance of Poolbeg's partnership with Johnson & Johnson, the commercial opportunity in a multi-billion-dollar market, and why management has continued to back the company with significant personal investmentDisclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

Most industrial property acquisitions include a Phase I Environmental Site Assessment. Many also include a Phase II. But what if some of the biggest environmental liabilities aren't covered by either? In this episode of Tank Talk, Shannon and Haley explore the environmental compliance risks that often go unnoticed during due diligence and why those risks can impact valuation, profitability, financing, insurance, and future operations long after a deal closes. From missing permits and poor recordkeeping to overdue inspections, infrastructure documentation gaps, and compliance history, the team discusses the operational environmental issues that buyers, sellers, lenders, and investors should evaluate before acquiring industrial assets. Whether you're involved in mergers and acquisitions, private equity, commercial lending, or industrial facility operations, this episode provides practical insight into the environmental risks that may not appear in a traditional Phase I or Phase II assessment. Because when it comes to industrial acquisitions, contamination isn't the only environmental liability worth investigating. Support the showintro/outro created with GarageBand

Up next is Part Two of the 2026 Main Camp Recap. We welcome Phase II pick Kamden Kaiser, followed by Phase I picks Jack Hair and Jackson Conroy to the show. The future is bright! Send us Fan MailAsk A Question!Merch Store Official WebsiteFacebookThis recording is the sole view of the members of the Dump & Chase Podcast.  This is a non-commercial fan production. We are not affiliated with or compensated by the Youngstown Phantoms, the United States Hockey League, or any league, club, or team.© 2026 Dump & Chase Podcast. All Rights Reserved

Key Topics CoveredThe Next Frontier in Weight Loss: GLP-1s & Myostatin InhibitorsThe Muscle Loss Problem: While GLP-1 receptor agonists (like Tirzepatide) are highly effective for weight loss, roughly 25% to 30% of the weight lost is actually lean body mass (muscle).The Pharmaceutical Solution: A recent Phase II clinical trial paired a GLP-1 drug with a myostatin inhibitor (which blocks the protein that caps muscle growth), successfully promoting lean mass development while shedding fat.The Practical Alternative: The hosts emphasize that resistance training and adequate protein intake achieve these exact same muscle-preserving results naturally, though large-scale studies on this are rarely funded because "you can't package and sell" exercise.The "Enhanced Games" & Tech-Bro GladiatorsA critique of the upcoming "Enhanced Games"—an Olympic-style event where performance-enhancing drugs are openly allowed.Using baseball's historic steroid era (e.g., Mark McGwire and Sammy Sosa) as an example, they discuss how performance enhancers amplify raw power margins without actually replacing foundational athletic coordination.A humorous look at the logical extreme of this trend: transitioning from myostatin inhibitors to full-blown CRISPR genetic engineering, drawing parallels to the movie Gattaca.The Rise of "Wellness Burnout"Wellness Maxing: The multi-billion-dollar wellness industry has created a exhausting "firehose" of protocols, leaving people overwhelmed by red-light masks, cold plunges, complex morning supplement "stacks," and hyper-optimized mattress coolers.The Power of Subtraction: The hosts advocate for simplifying your health routine rather than adding to it. They recommend automating simple meal choices, hitting a baseline of 20 minutes of daily exercise, and finding community-based, accountable activities like pickleball to naturally reduce stress and fight social isolation.

The U.S. government runs a program that will fund your company before you have a single customer — sometimes before you have a finished product at all.It's called SBIR, and in this episode John Martin breaks down exactly how he used it to go from an early-stage idea to a $1.9M U.S. Air Force funding increase, with a shot at a $30M+ award next. If you've got innovative technology and you've ever wondered whether the government would pay you to develop it, this is the conversation to watch.John is the founder of Bundle AR, an augmented reality and XR training platform now used across the Air Force, Space Force, Army, and the commercial world. We get into how SBIR Phase I and Phase II actually work, what TACFI and STRATFI are, why relationships beat writing proposals, and the single mistake most founders make when they try to sell to the government.––––––––––––––––––––––––––––––––––––––CHAPTERS––––––––––––––––––––––––––––––––––––––00:00 The $1.9M the Government Paid Bundle AR00:42 Who Is John Martin & What Bundle AR Does03:33 How He Got His First Government Check05:57 SBIR Explained: Getting Paid for an Idea07:48 Why SBIR Funding Froze (and Just Reopened)09:14 TACFI: The $1.9M Air Force Funding Increase11:54 STRATFI & the New $30M Award for 202616:01 Why Relationships Beat Writing Proposals17:55 How to Win Before the Contract Is Posted22:09 Live Demo: AR Training for the Military28:54 The Smartest Move: Two Revenue Streams29:32 The Truth About SBIR Mills32:24 The GovClose Gauntlet: Rapid Fire37:12 John's Radio Career: Cronkite, Kiss & Taylor Swift38:57 Advice for First-Time Government Contractors41:00 New Markets: Education, Healthcare & School Security44:04 What's Next for Bundle AR––––––––––––––––––––––––––––––––––––––RESOURCES MENTIONED––––––––––––––––––––––––––––––––––––––GovClose Program Overview (free 20-minute training):https://www.govclose.comSBIR / STTR Program (official):https://www.sbir.gov––––––––––––––––––––––––––––––––––––––ABOUT THE GUEST — JOHN MARTIN, BUNDLE AR––––––––––––––––––––––––––––––––––––––John Martin is the founder of Bundle AR (BUNDLAR), a Chicago-basedoperational intelligence platform company. Over 8+ years, Bundle AR hasbuilt a no-code augmented reality and XR-wearable platform that deliverstraining and knowledge "where work happens" for both enterprise and theDepartment of Defense. The company has won SBIR Phase I and Phase II awards,a $1.9M U.S. Air Force Tactical Funding Increase (TACFI), and is nowqualified for a Strategic Funding Increase (STRATFI). Past clients andengagements include Microsoft (Xbox), Thermo Fisher, Cleveland Clinic, theU.S. Air Force, Space Force, Michigan Air National Guard, and the U.S. Army.Learn more / connect with John:Website: https://www.bundlar.comEmail: john@bundlar.comLinkedIn: [paste John's LinkedIn URL here]––––––––––––––––––––––––––––––––––––––ABOUT RICK HOWARD––––––––––––––––––––––––––––––––––––––Rick Howard is a retired USAF Lieutenant Colonel and former DoD acquisitionsofficer who managed over $82 billion in federal contracts. He is the founderof GovClose and the DoD Contract Academy, with 400+ graduates working asgovernment contract consultants, federal account executives, and businessowners winning federal contracts.Get the GovClose Certification: https://www.govclose.com/sales-certification Our students learn the government contracting skills to :1. Start their own consulting business that can earn up to $400k as a "solopreneur" advising businesses that sell to the government.2. Land high paying sales executive jobs with companies in the public sector.3. Increase government contracting revenue for companies selling to the US government.

Falls Prevention After Stroke: What the Latest Research Reveals About Staying Safe and Mobile For many stroke survivors, the fear of falling is a constant companion. It’s there when you get up from the couch, when you navigate the kitchen, when you try to walk further than you did yesterday. That fear is rational, falls after a stroke are common, and their consequences can be serious. But according to Associate Professor Kate Scrivener, a stroke rehabilitation researcher at Macquarie University, that fear doesn’t have to define your recovery. In Episode 409 of the Recovery After Stroke podcast, Kate returns to the show where she first appeared in Episode 257 to discuss her HiWalk walking program and share the results of two major research projects: the published Phase II results of HiWalk, and a new systematic review focused specifically on exercise-based falls prevention after stroke. Who Is Kate Scrivener? Associate Professor Kate Scrivener leads stroke rehabilitation research at Macquarie University in Sydney, Australia. Her work sits at the intersection of real-world clinical practice and rigorous research. She doesn’t just study stroke recovery, she designs and tests the programs that can change it. Kate first appeared on this podcast to talk about HiWalk, a high-dose walking intervention designed to push the limits of what long-term stroke survivors can achieve. Now, with the results published, she’s back to talk about what the data actually showed and what it means for survivors who want to reduce their fall risk. The HiWalk Results: What Happened When 47 Survivors Walked Hard HiWalk was built on a straightforward but ambitious premise: what happens if stroke survivors, who have been living with their disability for years, are given a truly high-dose walking program? Not a gentle weekly session, but 43 hours of structured walking across just three weeks. The Phase II randomized trial enrolled 47 participants and produced results worth paying attention to. Attendance was 91%. Retention was 98%. For a physically demanding trial involving chronic stroke survivors, those numbers are remarkable, and they tell their own story about what survivors are capable of when given a real opportunity. For participants who were not already in active rehabilitation at the time of the trial, walking speed improved by 0.24 metres per second, a clinically significant gain. Self-efficacy, a measure of how confident participants felt in their own ability to walk and function, also improved significantly. The overall group walking speed trend was positive but did not reach statistical significance across the full cohort, partly because HiWalk was a Phase II feasibility trial, designed to test whether the program could be delivered safely and whether participants would complete it. It was not powered to detect large group-wide effects. What it demonstrated is that this kind of high-dose program is feasible, achievable, and produces real gains for the right participants. Why Falls Prevention After Stroke Is Harder Than It Sounds Falls after stroke are not simply a balance problem. They involve fatigue, reduced sensation, spasticity, cognitive changes, and the interaction between all of those things in the unpredictable terrain of daily life. Most stroke survivors are told to be careful. Very few are given a structured, evidence-based program designed specifically to reduce their risk. Kate’s systematic review, published in Clinical Rehabilitation in 2026, searched the global literature for exercise-based trials targeting falls prevention in community-dwelling stroke survivors. Only three trials worldwide met the inclusion criteria. That number alone says something significant. Falls after stroke are widely acknowledged as a major problem. The research base for solving it is thin. Of the three trials identified, exercise trended toward reducing the rate of falls, but the effect on the total number of people who fell was less clear. The standout result came from the FAST trial, which reduced fall rates by 33%. All three qualifying trials were conducted in Australia, raising important questions about whether these findings can be replicated in different healthcare systems with different levels of access to physiotherapy and structured exercise. What This Means for Stroke Survivors Right Now Kate’s research points to two things survivors and their families can act on. First, walking intensity matters. The HiWalk results suggest that long-term survivors who have plateaued in conventional rehabilitation may have more capacity than they or their clinicians assume. High-dose, structured walking appears to produce gains that lower-intensity programs don’t reach. If you’re a survivor who has been told to keep active but hasn’t been given a specific, progressive program, that’s worth a conversation with your physiotherapist. Second, exercise for falls prevention works, but it needs to be the right kind, delivered consistently. Gentle movement is valuable. But the evidence base Kate’s review maps out points toward structured, progressive exercise as the mechanism that shifts fall rates meaningfully. The FAST trial’s 33% reduction didn’t come from telling people to be more careful. It came from changing what they were physically capable of doing. Bill’s book, The Unexpected Way That A Stroke Became The Best Thing That Happened, explores the tools and mindset shifts that underpin a recovery built on action rather than waiting. You can find it at recoveryafterstroke.com/book. The Gap Between Research and Practice One of the most important threads in this conversation is the distance between what the research supports and what most survivors actually receive. Kate’s systematic review found only three qualifying trials globally. HiWalk’s feasibility results are published, but the next step, a large-scale Phase III trial, requires funding, time, and institutional will. For survivors, that gap can feel frustrating. The science is pointing in a clear direction. The programs aren’t yet widely available. Kate’s work is part of closing that distance. Listen to the Full Conversation Episode 409 with Associate Professor Kate Scrivener is available on all major podcast platforms, search Recovery After Stroke and on the Recovery After Stroke YouTube channel. If this show has helped you on your recovery journey, you can support it financially at patreon.com/recoveryafterstroke. This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. The post Walking More, Falling Less – A Researcher’s Mission to Stop Stroke Survivors Hitting the Ground appeared first on Recovery After Stroke.

Why This Episode MattersSabrina Maniscalco is one of the few people in quantum who has lived the full arc: two decades of academic work on open quantum systems and non-Markovian noise at Palermo, Turku, Edinburgh, and Helsinki, followed by founding Algorithmiq with three of her former researchers after an early Qiskit Camp. That trajectory matters now because Algorithmiq just had a landmark stretch — sole winner of the $2M Wellcome Leap Q4Bio prize for a quantum-enabled cancer drug discovery workflow, an €18M Series B, a global HQ move to Milan, and its Tensor Network Error Mitigation (TEM) function landing in IBM's Qiskit Functions catalog.If you're trying to make sense of where quantum software actually creates value before fault tolerance arrives — and what a credible "trajectory to advantage" looks like when paired with real clients in life sciences — this is a grounded, technically specific conversation with someone building it.EPISODE SPONSORThis episode is brought to you by Outshift, Cisco's incubation engine. The need for computational power is rapidly increasing in every sector. From drug discovery to material innovation to complex financial modeling, classical systems are reaching their absolute limits. It's time for a paradigm shift. The answer is a scalable quantum network, built on open standards and vendor-agnostic architecture. By uniting distributed quantum devices, you unlock limitless computational power.Learn more about the Cisco Universal Quantum Switch at Outshift.com.Go deeper with the blog post The switch that quantum networking has been waiting for.What We Get IntoWhy a background in open quantum systems and non-Markovian noise turned out to be unusually well-suited to running algorithms on noisy near-term hardwareThe actual science behind the Q4Bio winning workflow: simulating excited-state dynamics of a photosensitizer drug already in Phase II clinical trials, on up to 100 qubitsHow quantum-boosted DMRG works — and why it gives you a built-in benchmark against the best classical method via the bond dimensionThe tradeoff Sabrina would and wouldn't make between more qubits and lower noise, and why neutral atoms' slower sampling rates matter for chemistryWhy even fault-tolerant algorithms like quantum phase estimation still depend on getting state initialization and measurement rightAlgorithmiq's two-product structure: the Digital Quantum Interface (hardware-agnostic infrastructure) and the life sciences application frameworkHow methods built for chemistry are now opening doors into optimization and GenAI — and why that direction emerged from the work, not from a strategy deckWhat the move from Helsinki to Milan signals about the European quantum ecosystem and Algorithmiq's commercial scale-upHow an active learning pipeline is already proposing novel drug variants for synthesis in Prof. Sherri McFarland's labResources & LinksGuest & CompanyAlgorithmiq — The company Sabrina co-founded with Guillermo García-Pérez, Matteo Rossi, and Boris Sokolov; quantum software for life sciences and chemistry.Sabrina Maniscalco — University of Helsinki Research Portal — Publication record covering open quantum systems, non-Markovian dynamics, and quantum information.Sabrina Maniscalco — AI for Good Bio — Consolidated bio covering academic roles and advisory positions, including IQOQI Austria and CERN's Quantum Technology Initiative.The Q4Bio WinAlgorithmiq Wins $2M Wellcome Leap Q4Bio Prize — Company announcement detailing the photodynamic therapy workflow.Wellcome Leap — Q4Bio Prize Announcement — Funder's perspective on finalists and criteria.IBM Quantum Blog — Q4Bio Finalists — IBM's account of the workflow and quantum-classical integration.Funding & HQ MoveTech.eu — Algorithmiq's €18M Series B and Milan move — Coverage of Italy's largest quantum VC round to date.Quantum Computing Report — Algorithmiq Relocates to Milan — Strategic context including the Q4Bio win and IBM partnership.EU-Startups coverage — Investor lineup and Italy's National Quantum Strategy framing.Quantum Advantage & ToolingIBM Quantum Blog — The Dawn of Quantum Advantage — Includes Algorithmiq's TEM (Tensor Network Error Mitigation) function in the Qiskit Functions catalog.Algorithmiq & IBM Quantum Advantage Tracker — The heterogeneous materials experiment Algorithmiq and IBM put forward as a community benchmark.Silicon Republic interview with Sabrina — Useful prior context on her philosophy of using quantum to simulate quantum systems.Key Quotes & InsightsOn the foundation of the company's approach: "We learned very early what we thought were the bottlenecks of quantum computers — what you really need to worry about if you want to implement computation at scale." A direct line from Qiskit Camp Vermont to Algorithmiq's product strategy.On Q4Bio, in Sabrina's words: "This molecule is already in Phase II clinical trial. So it's not hydrogen. It's a real molecule." A useful counter to the common critique that quantum chemistry demos still live in toy-model land.On quantum-boosted DMRG (insight): In the worst case, the method matches the best classical technique; in the better case, it outperforms it — and the bond dimension tells you which regime you're in. Built-in benchmarking against the classical baseline.On the hardware tradeoff: Asked whether she'd prefer 100 higher-fidelity qubits or 200 noisier ones, Sabrina's answer is "it depends" — and the explanation about why neutral atoms' lower sampling rates limit chemistry use cases is one of the more concrete things you'll hear on platform tradeoffs.On strategy (insight): New verticals at Algorithmiq are ...

What if the most talked-about healing peptide in biohacking came from your own stomach — and carried a risk nobody in the space is talking about?BPC-157, nicknamed "the Wolverine Peptide," has taken over fitness forums, longevity podcasts, and regenerative medicine circles. The preclinical data on tissue repair is remarkable. But the same biological mechanism that drives its healing power is the exact mechanism tumors use to survive and grow.BPC-157 is a synthetic 15 amino acid sequence isolated from human gastric juice, first identified in the early 1990s. It drives tissue repair through six mechanisms: angiogenesis via VEGF upregulation, nitric oxide pathway modulation, FAK paxillin signaling activation, growth hormone receptor upregulation in tendons and ligaments, anti-inflammatory cytokine downregulation, and free radical scavenging for cell protection. An active Phase II randomized controlled trial is currently evaluating BPC-157 for acute hamstring muscle strain repair. Its pro-angiogenic properties raise a theoretical cancer risk in individuals with undiagnosed early-stage tumors. WADA has banned it for competitive athletes. The FDA has reclassified its availability and the FDA Pharmacy Compounding Advisory Committee is reviewing its status on the approved bulk substances list.Dr. Joy Kong talks about:00:00 Meet The Wolverine Peptide02:40 Discovered Inside Human Gastric Juice03:42 Six Pathways That Drive Healing07:33 The First Real Human Trial07:58 Why The FDA Cracked Down09:24 The Hidden Cancer RiskAdditional Resources:✨ Visit My Clinic: Chara Health

On the KMOJ Morning Show, Malik Rucker, founding Executive Director of V3 Sports, joined Freddie Bell for the "Community Builders Series" to discuss his North Minneapolis roots and the experiences that inspired his mission to invest in the community through health, wellness, and opportunity. A fifth-generation Northsider, Rucker reflected on the vision behind V3 Sports and how the organization has grown from a one-person operation into a major nonprofit serving families through fitness, aquatics, youth programming, and education. He explained that V3's mission extends far beyond athletics, focusing on building healthier communities, creating access, and strengthening economic empowerment through intentional partnerships with Northside businesses. Rucker also shared the pride he feels seeing the completed first phase of the V3 Center in action and looked ahead to Phase II, which will bring an Olympic-sized pool and expanded programming to further serve the community. 

We’re starting our read of Tales of Light and Life, a collection of short stories by the authors of the High Republic project. Join us as we discuss transitioning from Phase II to Phase III, Marda Ro sowing the seeds of the Nihil, and the aftermath of the fall of Starlight Beacon. For a list […]

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Power Metallic Mines Inc. (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1)Power Metallic is expanding its summer 2026 exploration program at the Nisk Project in Quebec with three advanced geophysical surveys — SQUIDs, gravity, and Ambient Noise Tomography — designed to pinpoint deeper Ni-Cu-PGE mineralization. These surveys run alongside a 30,000-metre diamond drill program already being mobilized for Q2 and Q3 2026. Investors in the critical metals space should take note as the company systematically targets extensions to the high-grade Lion Zone and new discoveries across the enlarged land package.Minaurum Silver Inc. (TSXV: MGG) (OTCQX: MMRGF) (FSE: 78M0)Minaurum has reported high-grade drill results from the Europa Sur Vein Zone at the Alamos Silver Project in Sonora, Mexico, highlighted by 3.20 metres of 882 g/t silver equivalent including a peak of 2,423 g/t AgEq over 0.95 metres. Elevated gold and copper values suggest the presence of a high-temperature feeder structure, substantially boosting resource expansion potential within the ongoing 50,000-metre Phase II drill program. Alamos already hosts a 55.4 Moz AgEq inferred resource.Sitka Gold Corp. (TSXV: SIG) (FSE: 1RF) (OTCQX: SITKF)Sitka Gold's first 2026 drill hole at the Blackjack deposit returned 94.0 metres of 1.79 g/t gold including 19.3 metres of 5.04 g/t gold from 1,093 metres depth — the deepest hole ever completed at the RC Gold Project in Yukon. The result extends high-grade gold approximately 370 metres below the existing resource pit and confirms strong continuity with last year's deep discovery. With four rigs active on a fully funded 60,000-metre program, the company is rapidly advancing a district-scale gold system hosting over 5.1 million ounces across indicated and inferred resources.CopAur Minerals Inc. (TSXV: CPAU)CopAur released a Preliminary Economic Assessment and a 52% increase in Mineral Resource Estimate for its Kinsley Mountain Gold Project in Nevada, now totaling 742,000 indicated ounces at 1.11 g/t gold. At the current spot gold price of US$4,500/oz, the project delivers a post-tax NPV of US$147 million and an IRR of 66% with a 1.5-year payback on pre-production CAPEX of US$81.8 million. For a small-cap company with a modest market capitalization, owning 100% of a permitted Nevada heap-leach gold project with these economics represents a potentially significant value proposition.Bottom Line: Today's stories highlight a sector in full motion — high-grade silver and gold drilling campaigns advancing in Mexico and the Yukon, paired with a Nevada gold project delivering compelling PEA economics. Critical metals exploration and near-term gold production potential are the dominant themes.Stay ahead of the market — follow AGORACOM for more breaking small-cap news and insights.

Vikings 2026 Expectations: Rookie Roles, Kyler Murray Fit, and Key Free-Agent Additions — Tyler Forness and Dave Stefano discuss realistic 2026 expectations for the new Minnesota Vikings, focusing on rookies, select UDFAs, and veteran additions. First-round DT Caleb Banks is framed as a long-term play, with year-one goals of staying relatively healthy, playing roughly 500–550 snaps, generating steady pressure, and building consistency. Second-round LB Jake Golday is projected primarily as an off-ball coverage linebacker used in sub-packages while he develops processing and run-fit skills, with caution against labeling him the next Andrew Van Ginkel. They outline modest roles for other picks (including Domonique Orange as a solid nose tackle, limited expectations for Caleb Tiernan and Jakobe Thomas, special-teams emphasis for Max Bredeson and Charles Demmings, skepticism about Demond Claiborne making the roster, and uncertain outlook for seventh-rounder Gavin Gerhardt) and note UDFAs to watch. Among veterans, Kyler Murray is expected to stay healthy and run Kevin O'Connell's offense with more consistency, while James Pierre, Jauan Jennings, and Isaiah Loudermilk are expected to be solid contributors. Timestamps: 00:00 Season Expectations Setup 00:14 Show Intro and Format 01:05 Why Expectations Matter 02:09 QB WR Workouts Note 02:33 Draft Class Kickoff 02:49 Caleb Banks Outlook 07:58 Jake Golday Role Debate 21:34 Domonique Orange Projection 23:34 Other Third Rounders 25:34 Jakobe Thomas and Safety Room 27:39 Harrison Smith Return Talk 30:04 Day Three Picks Begin 30:44 Fullback Role Unknown 31:48 Can Bredeson Win Job 33:05 No Friends Drafting 34:14 Demmings Development Plan 35:12 Claiborne Roster Doubts 40:44 Late Picks And UDFAs 41:49 Punter Battle And Cap 42:30 Kyler Murray Expectations 45:05 Fixing Explosives Vs Consistency 49:05 Free Agents Pierre Jennings 52:19 Loudermilk Camp Fit 53:49 Wrap Up And Schedule _______________________ ⭐️ Subscribe to us here! - https://www.youtube.com/@vikings1stskol92 ⭐️ Our Twitter can be found at @Vikings1stSKOL ⭐️ Our Discord at https://discord.com/invite/493z6mQXcN ⭐️ Tyler Forness can be read at A to Z Sports - https://atozsports.com/nfl/minnesota-vikings-news/ ⭐️ Submit questions: forms.gle/7LJkCAern9kdUkuD8 ⭐️ On Facebook - https://www.facebook.com/vikings1standskol ⭐️ Watch the live show here: https://youtu.be/-cl_KEGFuws Fan With Us!!! Tyler Forness @TheRealForno of Vikings 1st & SKOL @Vikings1stSKOL and A to Z Sports @AtoZSportsNFL, with Dave Stefano @Luft_Krigare producing this Vikings 1st & SKOL production, the @RealFornoShow. Podcasts partnered with Fans First Sports Network @FansFirstSN. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Vikings 2026 Expectations: Rookie Roles, Kyler Murray Fit, and Key Free-Agent Additions — Tyler Forness and Dave Stefano discuss realistic 2026 expectations for the new Minnesota Vikings, focusing on rookies, select UDFAs, and veteran additions. First-round DT Caleb Banks is framed as a long-term play, with year-one goals of staying relatively healthy, playing roughly 500–550 snaps, generating steady pressure, and building consistency. Second-round LB Jake Golday is projected primarily as an off-ball coverage linebacker used in sub-packages while he develops processing and run-fit skills, with caution against labeling him the next Andrew Van Ginkel. They outline modest roles for other picks (including Domonique Orange as a solid nose tackle, limited expectations for Caleb Tiernan and Jakobe Thomas, special-teams emphasis for Max Bredeson and Charles Demmings, skepticism about Demond Claiborne making the roster, and uncertain outlook for seventh-rounder Gavin Gerhardt) and note UDFAs to watch. Among veterans, Kyler Murray is expected to stay healthy and run Kevin O'Connell's offense with more consistency, while James Pierre, Jauan Jennings, and Isaiah Loudermilk are expected to be solid contributors. Timestamps: 00:00 Season Expectations Setup 00:14 Show Intro and Format 01:05 Why Expectations Matter 02:09 QB WR Workouts Note 02:33 Draft Class Kickoff 02:49 Caleb Banks Outlook 07:58 Jake Golday Role Debate 21:34 Domonique Orange Projection 23:34 Other Third Rounders 25:34 Jakobe Thomas and Safety Room 27:39 Harrison Smith Return Talk 30:04 Day Three Picks Begin 30:44 Fullback Role Unknown 31:48 Can Bredeson Win Job 33:05 No Friends Drafting 34:14 Demmings Development Plan 35:12 Claiborne Roster Doubts 40:44 Late Picks And UDFAs 41:49 Punter Battle And Cap 42:30 Kyler Murray Expectations 45:05 Fixing Explosives Vs Consistency 49:05 Free Agents Pierre Jennings 52:19 Loudermilk Camp Fit 53:49 Wrap Up And Schedule _______________________ ⭐️ Subscribe to us here! - https://www.youtube.com/@vikings1stskol92 ⭐️ Our Twitter can be found at @Vikings1stSKOL ⭐️ Our Discord at https://discord.com/invite/493z6mQXcN ⭐️ Tyler Forness can be read at A to Z Sports - https://atozsports.com/nfl/minnesota-vikings-news/ ⭐️ Submit questions: forms.gle/7LJkCAern9kdUkuD8 ⭐️ On Facebook - https://www.facebook.com/vikings1standskol ⭐️ Watch the live show here: https://youtu.be/-cl_KEGFuws Fan With Us!!! Tyler Forness @TheRealForno of Vikings 1st & SKOL @Vikings1stSKOL and A to Z Sports @AtoZSportsNFL, with Dave Stefano @Luft_Krigare producing this Vikings 1st & SKOL production, the @RealFornoShow. Podcasts partnered with Fans First Sports Network @FansFirstSN. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of BioTalk with Rich Bendis, Sam Gussman-Toh, Portfolio Manager for the Small Business Program at ARPA-H, joins the conversation to discuss how the agency is creating new pathways for small businesses developing ambitious health technologies. Sam explains how the ARPA-H model differs from traditional federal funding programs, with a focus on moonshot health solutions, program manager-led portfolios, milestone-driven contracts, and a strong emphasis on moving technologies toward real-world use. He also discusses how the Small Business Program supports SBIR and STTR performers through Phase I, Phase II, Direct to Phase II, and Fast Track awards. The conversation highlights how ARPA-H is working with ambitious small businesses, including non-traditional companies and early-stage startups that may be working with the federal government for the first time. Sam also shares how commercialization support is built into the program, including ARPA-H's Entrepreneur-in-Residence partnership with BioHealth Innovation. Through that relationship, BHI EIRs help performers strengthen regulatory strategy, intellectual property planning, go-to-market strategy, reimbursement considerations, and other key commercialization needs. Sam also discusses ARPA-H's draft Small Business Program solicitation, the upcoming virtual Proposers' Day on June 11, and what companies should know about the application process, topic areas, technical pitches, and future funding opportunities. Editing and post-production work for this episode was provided by The Podcast Consultant. Sam Gussman-Toh is Portfolio Manager for the Small Business Program at ARPA-H, where he coordinates and oversees the agency's SBIR/STTR awards and commercialization support services for participating small businesses. Sam joined ARPA-H in 2022 and wrote the agency's first SBIR/STTR solicitation. He has held several roles in the Office of Commercialization and has worked closely with Program Managers to build the agency's commercialization infrastructure and strategy. Previously, Sam designed and managed rapid prototyping programs across agencies in the Department of War. His technical background is in computer science, with interests in computer vision, autonomous robotic systems, and computational pathology.

Acute respiratory distress syndrome (ARDS) induced by COVID-19 was a leading cause of severe illness and death during the pandemic, driven by an intense innate immune response, hyperinflammation, and a decrease in lymphocytes. Mesenchymal stromal cells (MSCs) represent a potential therapeutic option for ARDS due to their ability to modulate the immune system and inflammation. Our guests report results from a Health Canada–regulated Phase I and Phase II trials evaluating freshly cultured umbilical cord–derived MSCs in patients with COVID-19-related ARDS, including assessments of safety, maximum feasible tolerated dose, and preliminary efficacy. Their work explores a therapeutic strategy to improve ARDS outcomes using MSCs, which will be important for optimizing and targeting future cellular therapies.GuestDuncan Stewart, MD, Ottawa Hospital Research Institute and University of Ottawa, CanadaElmira Safaie Qamsari, Ottawa Hospital Research Institute, CanadaHostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting DocumentsPaper link: Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials About Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. X: @StemCellReportsAbout ISSCRAcross more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to advancing stem cell research and its translation to medicine.ISSCR StaffKeith Alm, Shuangshuang Du, Kym Kilbourne, Megan Koch, Jack Mosher, and Hunter Reed

JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210). LINK TO FULL TRANSCRIPT

As cancer vaccines move into Phase II and III clinical trials, it isincreasingly important for surgeons to understand their role in thisevolving landscape. What exactly are these vaccines, how do they work,and what should the surgical community know about theirimplementation? Join BTK surgical education fellows Kara Button andMichelle LaBella as they sit down with Professor Robert Jones to breakdown the science of mRNA vaccines, the logistics of tissueprocurement, and the future of cancer care.Hosts:- Professor Robert Jones: Consultant Liver Surgeon, Liverpool UniversityHospitals; UK National Institute for Healthcare Research, Co-Lead forthe Cancer Vaccine Innovation Pathway, Bowel Cancer UK and RoyalCollege of Surgeons UK Lead for Research into Advanced Bowel Cancer,and UK Chief Investigator for the BNT122-01 trial.https://www.linkedin.com/in/robert-jones-6103722a/- Kara Button, DO: General Surgery Resident, Maine Medical Center;Behind the Knife Surgical Education Fellow.- Michelle LaBella, MD: General Surgery Resident; University of NorthCarolina; Behind the Knife Surgical Education Fellow.References:https://clinicaltrials.biontech.com/trials/BNT122-01Jones RP, Lee LYW, Corrie PG, et al. Individualized cancer vaccinesversus surveillance after adjuvant chemotherapy for surgicallyresected high-risk stage 2 and stage 3 colorectal cancer: protocol fora randomized trial. BJS. 2023;110(12):1883-1884.doi:10.1093/bjs/znad332https://pubmed.ncbi.nlm.nih.gov/37856683/Tie J, Wang Y, Loree JM, et al. Circulating tumor DNA-guided adjuvanttherapy in locally advanced colon cancer: the randomized phase 2/3DYNAMIC-III trial. Nat Med. 2025;31(12):4291-4300.doi:10.1038/s41591-025-04030-whttps://pubmed.ncbi.nlm.nih.gov/41115959/Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigenvaccines stimulate T cells in pancreatic cancer. Nature.2023;618(7963):144-150. doi:10.1038/s41586-023-06063-yhttps://pubmed.ncbi.nlm.nih.gov/37165196/https://www.cancer.ox.ac.uk/research/lynchvax#:~:text=The%20LynchVax%20program%2C%20funded%20by,individuals%20with%20this%20genetic%20conditionPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

João Canêdo of Fenix Gold, own and operated by Rio2, joins Trevor for an MSD interview following last week's site visit to the Fenix Gold Project. João provides a thorough update on the mine's construction, which is close to complete. The company has produced dore leading up to its full commissioning. But Fenix continues to think long-term with the strategy of a Phase II. He walks us through those ideas of how to truly optimize the mine plan.

Big Breaking! Opinion Poll Gives Clear Majority to BJP | 60/142 in Phase II, 154/294 Overall

Listen below or click here for full show notes Main Mission, Part 1 (with an appropriate sound effect) Starfleet Academy cancelled Star Trek: Starfleet Academy EP Confirms Season 2’s Major Risk ‘Star Trek: Starfleet Academy’ Canceled After Two Seasons Why Paramount Plus Ended Star Trek: Starfleet Academy After Two Seasons Star Trek: Starfleet Academy Ending With Season 2 Breaking — STAR TREK: STARFLEET ACADEMY Ends with Season 2, Wrapping Known Kurtzman-Era Productions – TrekCore.com ‘Star Trek: Starfleet Academy’ To End With Season 2 At Paramount+ ‘Star Trek: Starfleet Academy’ to End With Season 2 (EXCLUSIVE) William Shatner Speaks Out After Starfleet Academy’s Cancellation: ‘That Aspect Of Star Trek I’ve Always Loved’ William Shatner Breaks Silence on Surprise ‘Star Trek: Starfleet Academy’ Cancelation – Men’s Journal Paramount+ Is Dismantling Star Trek After a Historic 9-Year Streaming Run Star Trek is Adrift: Why ‘Starfleet Academy’ is Folding After Season 2 The Real Reason for Paramount Dismantling Star Trek’s 9-Year Streaming Run Isn’t What You Think David Ellison On Cost Savings, Growth, The Tech Stack & AI As WBD Merge Star Trek: Starfleet Academy Cancellation Explained By Robert Picardo These 7 Rumored ‘Star Trek’ Shows Could Save the Franchise After ‘Starfleet Academy’s Cancelation The Star Trek Series Decades In The Making Lasted Just Over 2 Months Why Starfleet Academy's Cancelation Has Me Worried About The Star Trek Franchise ‘Star Trek: Starfleet Academy’ Offers the Franchise a Unique Way Forward STAR TREK’s TV Future Explained by Alex Kurtzman Amid Paramount Skydance Changes — GeekTyrant Subspace Chatter STAR TREK: YEAR ONE Has Already Been Pitched To Paramount Skydance STAR TREK: YEAR ONE Pitch Has Officially Reached Paramount Skydance -CBR “Star Trek: Year One” Has Been Pitched – Dark Horizons Star Trek: Starfleet Academy Fan Petition Hits Milestone After Paramount+ Cancellation Petition · Renew ‘Star Trek: Starfleet Academy' for a third season – United Kingdom · Change.org Star Trek: Scouts Final Episodes Released on YouTube Star Trek: The Next Generation Star Remembers When They Weren’t Real Trek | Den of Geek NickALive!: The 16th Anniversary Bundle! | Star Trek Online 25 Years Later, Star Trek Has Revealed The Hidden Reason Starfleet Actually Began PREVIEW — Inside IDW's THE ART OF STAR TREK: LOWER DECKS – TrekCore.comAndy Weir Apologizes To Alex Kurtzman After Slamming Modern STAR TREK ‘Project Hail Mary' Author Stirs Controversy Over Failed Star Trek Pitch, Then Apologizes To Alex Kurtzman – TrekMovie.com Andy Weir ‘Star Trek’ Comments Draw Fire From Author Don Winslow ‘Star Trek’: How The Beatles Inspired Kirk and Spock's Reboot Bond Leonard Nimoy’s Positive Reaction To Star Trek: DS9’s ‘Trials and Tribble-ations’ Star Trek: Prodigy Wins Emmy Award Land The Shuttlecraft Galileo by Brian Mix — Kickstarter STAR TREK: STRANGE NEW WORLDS Season 4 Premiere Expected In Late Summer Toy Fair ’26: Nacelle announces Lucille Ball & Gene Roddenberry action figures Action Figure Insider » Nacelle Toys Reveal New Star Trek Products at #Wondercon2026 Here are links to 57  additional stories.broken out by series, movies and other categories. CLASSIC TV SERIES (in order of premiere) Star Trek: The Original Series (1966 – 1969) [3 seasons] 57 Years Ago Today, Star Trek Released A Time Travel Masterpiece That The Franchise Has Never Beaten – ComicBook.com ‘Star Trek' Actress Admits She Had a Crush on William Shatner Star Trek: The Next Generation (1987 – 1994) [7 seasons] 10 Star Trek: The Next Generation Episodes To Skip On A Rewatch Star Trek: TNG’s Chain of Command Is Mandatory Viewing for Every Sci-Fi Fan Star Trek: Deep Space Nine (1993 – 1999) [7 seasons] One Of Star Trek's Best Episodes Was Created Out Of Spite Star Trek: Voyager (1995 – 2001) [7 seasons] The Star Trek Episode That Only Exists Because Of A Sex Joke STREAMING SERIES AND MOVIES (in order of premiere) Star Trek: Picard (2020 – 2023) [3 seasons] Why 1 Returning Star Trek: The Next Generation Star Was Disappointed by Picard Season 3's Reunion – ComicBook.com ‘Star Trek: Picard’ Never Confirmed ‘Voyager’s Alternate Future Captain La Forge Reveal Star Trek’s Marina Sirtis Explained Why Comparing Her Experience On Picard Season 3 To TNG Was ‘Depressing’ | Cinemablend Star Trek: Lower Decks (2020 – 2024) [5 seasons] Star Trek: Lower Decks Made An Abandoned Vulcan Character Franchise Canon Star Trek: Strange New Worlds (2022 – present) [4th season yet to premier, 5th/final season filmed] Star Trek director ‘was very proud of’ arguably the worst Strange New Worlds episode STAR TREK: STRANGE NEW WORLDS Season 4 Promises “Classic” Episodes Alongside Bold New Experiments Star Trek: Starfleet Academy [2026 – present] [season 2 will end series] Star Trek Officially Confirms It Now Follows One of the Oldest Star Wars Rules – ComicBook.com Starfleet Academy Showrunner Teases Season 2: ‘The Dynamics You Thought Were Going to Be One Way Forever Start to Slowly Shift' – IGN REVIEW – Star Trek: Starfleet Academy “Rubincon” – Trek Central Starfleet Academy is Star Trek (despite what so-called fans would have you believe) Star Trek's Most Divisive Spin-Off Warps Past a Major Streaming Milestone Starfleet Academy's Finale Improved Because It Removed Terrible Star Trek Characters Star Trek: Starfleet Academy season 1 finale provides 6 unexpected glimpses of the future Star Trek: Starfleet Academy Is The Greatest Argument For The Return Of Long TV Seasons Yes, There Will Be a Starfleet Academy Season 2. Here’s What We Know About It – Reactor KUOW – ‘Starfleet Academy’ isn’t for everybody, but ‘Star Trek’ still is (Did ‘Star Trek’ jump the targ?) 39 Years Later, The Star Trek Franchise Just Put Itself On Trial — Again Jonathan Frakes Reacts to ‘Absurd’ Star Trek: Starfleet Academy Gag The United Federation of Planets Has a War College Now — Are We Gonna Talk About It? – Reactor Star Trek just fumbled what could have been an all-time villain reveal Star Trek: 3 Best Things About Starfleet Academy Season 1 (& The 5 Worst) – ComicBook.com Starfleet Academy season 1 finale makes it painfully obvious what's coming for the Doctor in season 2 Star Trek: Starfleet Academy Calls Out a Missing Piece of Starfleet Canon 60 Years Later Star Trek actor was Jonathan Frakes’ ‘secret weapon’ on Starfleet Academy Star Trek icon praises Starfleet Academy’s ‘great’ Khionian actor unannounced “Star Trek: Legacy” series Star Trek: Legacy Is ‘Never Gonna Happen’ Says TNG Icon Trek series that never were, for one reason or another, [such as “Phase II”] The Lost ‘Star Trek' Movies and Shows That Almost Happened—and the Stories Behind Them THEATRICAL MOTION PICTURES (in order of premiere) Star Trek: First Contact (1996) Tom Hanks Wanted To Play An Extremely Important Star Trek Character Fourth Kelvin-timeline movie [cancelled in 2025 after many false starts] Why Star Trek 4 Isn't Happening OTHER MEDIAStar Trek video games/board games We Boldly Go Hands-On With Star Trek: Infection & Live To Tell About It Star Trek toys/collectibles/other merchandise March STAR TREK Merch Roundup: Klingon Weapons, STARFLEET ACADEMY Pins, New EXO-6 Figures, and More! – TrekCore.com Star Trek Comics/graphic novels/magazines Star Trek: The Last Starship #8 Exclusive Preview Star Trek: The Last Starship #6 – Comic Book Preview MISCELLANEOUS Paramount+ / Paramount Skydance David Ellison On Cost Savings, Growth, The Tech Stack & AI As WBD Merger Star Trek related science news A Modest Proposal: Star-Trek-like Communicator Badges for Siri | Scientific American Franchise-wide/Miscellaneous All 10 Star Trek Series Finale Episodes, Ranked – AOL All 14 Star Trek Movies Ranked According To Rotten Tomatoes Paramount has a Star Trek Strategy Problem. Here Are Five Ways to Fix It. 10 essential Star Trek episodes to watch after Starfleet Academy season 1 Every Star Trek First Season Ranked Worst to Best – Reactor Everything We Know About the Future of ‘Star Trek’ Column | What ‘Star Trek' teaches us about the 21st century – The Pitt News Rod Roddenberry on Carrying Forward the STAR TREK Legacy – Nerdist The 10 Best Star Trek Episodes of All Time – ComicBook.com Where did ‘Star Trek’ go? And what does it mean for the future of Paramount – and movie theaters? – East Idaho News 10 Most Uncomfortable Star Trek Scenes Of All Time Star Trek Should Boldly Go Back To Network TV ‘Star Trek: The Next Generation’ Trivia: Take the World’s Hardest Quiz Actor Watch Jonathan Frakes Says STARFLEET ACADEMY Could Be His Last Time Directing STAR TREK — GeekTyrant Shatner's 95th sparks global Star Trek party Shatner Reveals Why He Avoids Watching Star Trek Main Mission, Part 2 (with an appropriate sound effect) Star Trek: The Cruise 2026 End Of Show It’s about time to refill the dilithium chamber and get on out of here. Find Clinton at Comedy4Cast Find Chuck and Kreg at Technorama Podcast (MUSIC IN) If you liked the show, please be sure to tell a friend about it. And subscribe, so you’ll never miss an episode. We’d love to hear from you. Follow us on BlueSky (@thetopicistrek), visit our Facebook page or call us at 816-TREKKER, that’s (816) 873-5537 Don’t put on the red shirt! END RECORDING – HAILING FREQUENCIES CLOSED

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91)A U.S. federal court has largely denied a joint motion to dismiss Quantum BioPharma's USD $700 million lawsuit against CIBC World Markets and RBC Dominion Securities, which alleges illegal market manipulation through spoofing practices. The ruling marks a significant legal milestone for the company, allowing the case to move forward. Beyond the courtroom, Quantum continues to advance its drug development pipeline targeting multiple sclerosis and alcohol misuse disorders.Tartisan Nickel Corp. (CSE: TN) (OTCQX) (FSE)Tartisan has proposed a $1 million non-brokered flow-through financing at $0.38 per share to support ongoing exploration at its Kenbridge nickel-copper-cobalt project in Northwestern Ontario. The financing reflects continued commitment to advancing a critical minerals asset in a region increasingly viewed as strategically important for battery metals and supply chain security.Nine Mile Metals Ltd. (CSE: NINE) (OTC PINK: VMSXF) (FSE: KQ9)Nine Mile reported strong certified assay results from drill hole WD-25-2B at the Wedge Mine in the Bathurst Mining Camp. The hole returned 3.17% copper equivalent over 15.00 metres, including a higher-grade interval of 5.99% copper equivalent over 6.84 metres. Visible high-grade copper mineralization at the base of the hole suggests further upside potential as the company prepares for its Phase 3 drill program in May.NevGold Corp. (TSX-V: NAU) (OTCQX: NAUFF) (Frankfurt: 5E50)NevGold achieved up to 99% gold recovery in Phase II metallurgical testing on oxide antimony-gold material at its Limousine Butte Project in Nevada. Sequential leaching for antimony and gold demonstrated minimal impact on gold recoveries, supporting the potential for a combined antimony-gold operation. The company also identified additional antimony mineralization at surface within a historical waste dump.Yukon Metals Corp. (CSE: YMC) (FSE: E770) (OTCQB: YMMCF)Yukon Metals released results from its first drill program at the Star River property near the past-producing Ketza mine in the Yukon. Drilling intersected 11.7 g/t gold within a polymetallic vein system, alongside values of up to 183 g/t silver and 10.6% lead. A drone magnetic survey outlined a 1-kilometre structural corridor, and the company expanded its land position by acquiring the historic Stump silver-lead claims along the same trend.Bottom Line: Today's headlines highlight strong momentum across the small-cap mining and biotech sectors, from significant court developments and financing initiatives to high-grade drill results and advancing metallurgical programs.Stay ahead of the market by following AGORACOM for more breaking small-cap news and insights.And don't forget to check out our podcast for deeper dives into the stories shaping the small-cap market.

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Nextech3D.AI Corporation (CSE: NTAR) (OTCQB: NEXCF) (FSE: 1SS)CEO Evan Gappelberg has purchased an additional 500,000 common shares on the open market at $0.12 CAD, bringing his total ownership to more than 30 million shares. The insider buy reinforces management's confidence in the company's AI-powered event technology platform, which has reported 95% gross margins and 59% year-over-year revenue growth. With 50 new enterprise contracts signed since January and profitability achieved at its Krafty Labs division, the company believes its current valuation does not reflect its growth trajectory.Thunderstruck Resources Ltd. (TSXV: AWE) (OTC: THURF)Zhaojin International Gold Co. Ltd. (SZSE: 000506), one of China's leading gold producers with annual output of 600,000 to 700,000 ounces, is making a strategic investment in Thunderstruck for approximately 19.99% of the company at $0.11 per share, totaling about CDN$1.56 million. This marks Zhaojin's first investment in an exploration company and validates Thunderstruck's district-scale gold, silver, zinc and copper portfolio in Fiji. Zhaojin will receive a board seat and the right to appoint a Vice President of Exploration.Advanced Gold Exploration Inc. (CSE: AUEX) (FSE: ZF2) (OTCID: AUHIF)The 2025 drill program at Buck Lake has confirmed massive sulphide mineralization along a 3,000-metre electromagnetic corridor in Ontario's Batchawana Greenstone Belt. Drill hole BL-25-01 returned 9 metres averaging 510 ppm copper, with a peak of 1,180 ppm. BL-25-03 intersected 16.5 metres averaging 545 ppm copper, with highs up to 1,200 ppm. The polymetallic VMS signature, comparable to systems such as Kidd Creek and the Horne Mine, suggests the current shallow drilling may represent only the upper portion of a larger mineralized structure.Minaurum Silver Inc. (TSXV: MGG) (OTCQX: MMRGF) (FSE: 78M)Minaurum's Phase II drill program at the Alamos Silver Project in Sonora, Mexico, has delivered high-grade results from the Quintera Vein Zone. Hole AL26-180W returned 5.30 metres grading 570 g/t silver, including 2.50 metres at 1,024 g/t silver. Hole AL26-188 intersected 5.80 metres at 581 g/t silver. Notably, Quintera was not included in the company's initial resource estimate and is expected to be incorporated into an updated estimate in the second half of 2026. With six rigs active on a fully funded 50,000-metre program, Minaurum continues to expand high-grade zones across multiple vein systems.Bottom Line: Today's headlines highlight insider conviction, international strategic investment, and strong drill results across the small-cap mining and technology sectors. From a CEO increasing his personal stake to a major Chinese gold producer backing a Fiji-based explorer, these developments point to growing confidence in companies demonstrating tangible operational progress.Stay ahead of the market by following AGORACOM for more breaking small-cap news and insights.And be sure to check out our podcast for deeper dives: https://open.spotify.com/show/74mVPkfalaWXFYY65A2XLM

Pancreatic cancer remains one of the most difficult cancers to treat, largely because its dense tumor microenvironment makes it difficult for chemotherapy drugs to reach their target. This often leads to poor patient outcomes and underscores the urgent need for new therapeutic strategies to overcome these barriers. In this episode of Curing with Sound, Jae Young Lee, MD, PhD, professor and researcher at Seoul National University Hospital, shares his work exploring focused ultrasound as a noninvasive treatment option for pancreatic cancer. He explains how this technology creates subtle mechanical stress within the tumor, helping to open up its structure so chemotherapy can work more effectively. Dr. Lee also shares encouraging results from his Phase II clinical trial and looks ahead to a pivotal Phase III study, offering new hope for improving patient outcomes. Discussion highlights: A New Treatment Strategy: Focused ultrasound technology shows promise for addressing the unique challenges of pancreatic cancer, enabling precise tumor targeting while preserving critical surrounding structures. From Research to Reality: Learn how Seoul National University Hospital, a designated Focused Ultrasound Center of Excellence, is integrating this technology into clinical care while advancing research across oncology, neurosurgery, and pain management. Seoul National University Hospital Website EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org FOCUSED ULTRASOUND TREATMENT SITES https://www.fusfoundation.org/the-technology/treatment-sites/ SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/    

This week, we’re wrapping up Path of Vengeance by Cavan Scott and discussing the manga Edge of Balance: Precedent. Join us as we discuss Marda’s character arc, transitioning into Phase III of the High Republic project, and our feelings about Phase II overall. For a list of Black-owned bookstores to order from, now and always, […]

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Featuring an interview with Dr Ravin Ratan, including the following topics: Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: Results from the Phase III DeFi trial (0:00) Onset and resolution of ovarian toxicity with nirogacestat treatment for desmoid tumors: Updated safety analyses from the DeFi trial (4:37) Subgroup analysis of the Phase II part of the RINGSIDE Phase II/III trial of varegacestat for desmoid tumors (7:39) Surgical management of desmoid tumors; cryotherapy in the treatment of extra-abdominal desmoid tumors (10:30) CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics: VAYHIT1: A multicenter randomized, double-blind, Phase III trial evaluating ianalumab versus placebo in addition to first-line corticosteroids for patients with primary immune thrombocytopenia (ITP) (0:00) Secondary analysis results from VAYHIT3, a Phase II study of ianalumab for patients with primary ITP previously treated with at least 2 lines of therapy (8:15) Improved health-related quality of life and bleeding scores with the oral Bruton tyrosine kinase inhibitor rilzabrutinib in the open-label period of the multicenter Phase III LUNA 3 study for adults with ITP (12:23) Romiplostim for chemotherapy-induced thrombocytopenia in patients with colorectal, gastroesophageal and pancreatic cancer: A global Phase III randomized, placebo-controlled trial (16:01) CME information and select publications

The second ousting of Vinay Prasad from FDA in the past eight months won't lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of the news ahead of the coming midterm elections. On the latest BioCentury This Week podcast, Washington editor Steve Usdin lays out why the former CBER director was pushed out at FDA and what's next for the agency following his departure.BioCentury's editors also discuss the next wave of therapies for idiopathic pulmonary fibrosis, including whether new candidates might go beyond slowing disease to halt or even reverse progression, the biological complexity that makes fibrosis so challenging, and what the 20-plus Phase II programs could teach the field about fibrosis biology.Also up for discussion were recent clinical wins — as well as more complicated readouts — from psychedelic therapies; plus the latest data updates from obesity treatments, with a focus on amylin agonists.View full story: https://www.biocentury.com/article/658698#FDA #IdiopathicPulmonaryFibrosis #PsychedelicTherapies #ObesityDrugs #AmylinAgonists00:00 - Introduction01:56 - Prasad's Departure15:27 - Fibrosis Therapies23:35 - Psychedelics Clinical Catalysts28:24 - Obesity UpdatesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Listen below or click here for full show notes Main Mission, Part 1 Star Trek: Starfleet AcademySeason 1, Episode 7“Ko’Zeine”Written by Alex Taub & Eric Anthony GloverDirected by Andi Armaganian Subspace Chatter Star Trek: Starfleet Academy Season 2 Wraps Filming! – Trek Central Land The Shuttlecraft Galileo by Brian Mix — Kickstarter Star Trek: Starfleet Academy Showrunners on Deep Space Nine Star Trek Finally Closes a Plot Hole That's Haunted The Original Series 59 Years Later The twelve newly announced ships joining the collection include: The Texas-class USS Aledo from Lower Decks The android-manned Synth attack ship from Picard The USS Damocles, the Klingon-constructed false Federation starship from Strange New Worlds The USS Athena from Starfleet Academy A one-nacelled Freedom-class variant of the USS Cerritos The classic Shuttlecraft Galileo from The Original Series The USS Kelcie Mae from Strange New Worlds An XL-sized model of the USS Cerritos with its hull removed The Nova Flyer vessel from Prodigy The USS Adventure from Strange New Worlds A Gorn Hunter ship from Strange New Worlds An XL-sized USS Protostar featuring a deployed proto-warp drive Fanhome Announces Expansion to STAR TREK STARSHIPS Collection, with Additions from STARFLEET ACADEMY, STRANGE NEW WORLDS, and More Quick mention of the Warner Bros., Netflix, Paramount continuing saga article. Here are links to 83 additional stories.broken out by series, movies and other categories. You’ll find articles on everything from How Lucille Ball Saved Star Trek to the 1980’s attempt to make a Starfleet Academy movie.. CLASSIC TV SERIES (in order of premiere) Star Trek: The Original Series (1966 – 1969) [3 seasons] The Original Drafts for Star Trek’s Opening Narration – Neatorama How Lucille Ball Saved ‘Star Trek’ But Lost Her Studio (Exclusive) | Woman’s World Star Trek: The Next Generation (1987 – 1994) [7 seasons] Michael Dorn almost quit Star Trek The Next Generation after just two seasons in the role of Worf – 3DVF Why ‘Star Trek' Star Couldn't Sleep While Playing His Iconic Role – Parade Star Trek: Deep Space Nine (1993 – 1999) [7 seasons] Star Trek: Deep Space Nine Was Inspired By This Hit ’50s Western Series Star Trek: Voyager (1995 – 2001) [7 seasons] ‘Star Trek' Icon, 72, Admits His Character’s Beloved Trait Was a ‘Mistake’ Star Trek: Enterprise (2001 – 2005) [4 seasons] Why Star Trek Bosses Were Afraid Scott Bakula Would Pass On Enterprise Until The Last Minute Why Was Star Trek: Enterprise Cancelled and Can It Be Revived? – Cancelled Sci Fi STREAMING SERIES AND MOVIES (in order of premiere) Star Trek: Discovery (2017 – 2024) [5 seasons] Star Trek: Discovery Cancellation Was Surprising, Says Mary Wiseman Star Trek: Strange New Worlds (2022 – present) [4th and 5th seasons] Jonathan Frakes On Directing Jack Quaid’s Hilarious ‘Riker Maneuver’ In Star Trek Crossover Star Trek: Starfleet Academy [2026 – present] [renewed for second season] REVIEW – Star Trek: Starfleet Academy “Come, Let’s Away” – Trek Central ‘Starfleet Academy’ Decides Everyone Needs a Harsh Lesson Star Trek’s Divisive New Series Just Proved The Doubters Wrong Star Trek: Starfleet Academy Episode 6 Review – Come, Let's Away | Den of Geek Star Trek: Starfleet Academy Episode 6 Review – Return to the Miyazaki! – IGN Has ‘Star Trek: Starfleet Academy’ just unleashed its very own Khan? | Space Star Trek Finally Reveals Voyager’s Official Replacement – ComicBook.com Star Trek’s New TV Series is Changing the Galaxy More Than Any Other Show Before It – ComicBook.com Star Trek: Starfleet Academy Proves Just How Influential Spock Truly Was Did Starfleet Academy nail its ‘love letter’ to Star Trek: DS9? After Starfleet Academy’s DS9 Episode, I Know How The Star Trek Series Could Bring Back A Legacy Character | Cinemablend I Was Surprised At How Real Star Trek: Starfleet Academy's Mind Space Was, But The Stars Said It Had A Funny Downside Starfleet Academy Finally Finds The Sweet Spot For Storytelling Starfleet Academy Can Succeed Where Every Other New Star Trek Series Has Failed NickALive!: The Cadets Return Home for the Holidays in New ‘Star Trek: Starfleet Academy’ Episode ‘Ko'Zeine’ | First Look Star Trek's Epic New Klingon Villain Return Officially Addressed by Star – ComicBook.com Starfleet Academy Episode 7 “Ko’Zeine” Pits Ambition Against Family Duty as Cadets Return Home + 10 New Photos – TREKNEWS.NET | Your daily dose of Star Trek news and opinion Star Trek: Starfleet Academy’s Hidden Connection To Chris Pine’s Captain Kirk Star Trek Officially Confirms a Major Klingon Theory (& Sets Up a New Problem) – ComicBook.com Paramount+'s Unexpected Sci-Fi Hit Officially Wraps Season 2 Very Soon [Exclusive] Interview — STAR TREK: STARFLEET ACADEMY's George Hawkins on His “Fishboy” Alter Ego, Cadet Darem Reymi – TrekCore.com ‘Star Trek’ Star Says He Was ‘Scared' to Play His Groundbreaking Role — Here's Why Star Trek: DS9 actor was ‘amazing’ to work with on Starfleet Academy Starfleet Academy Episode 7: One Wedding and a Burglary Star Trek: Starfleet Academy’s George Hawkins Admitted Darem’s Episode Made One ‘Brutal’ Change ‘Starfleet Academy’ Gives Its Kids (and Itself) the Grace to Find Their Own Path 61 Years Later, Star Trek Is Taking A New Approach To The Captain Kirk Question 33 Years Later, Star Trek Just Released a Secret Sequel to a Classic Next Generation Episode – ComicBook.com Healing Old Wounds and New Beginnings in Starfleet Academy Episode 8 “The Life of the Stars” + 17 New Photos – TREKNEWS.NET | Your daily dose of Star Trek news and opinion ‘Star Trek: Starfleet Academy’ Fan Backlash Explained | The Mary Sue ‘Star Trek: Starfleet Academy’: Bella Shepard Reveals How Genesis’ Setback Just Set up Season 2 33 Years On, Star Trek Officially Reverses a Decision The Next Generation Admitted Was a Mistake – ComicBook.com Star Trek: Starfleet Academy Actors Wrao Season 2 Filming: Impact On Paramount+ Franchise As ‘Star Trek’ Nears 60, Showrunners Say It Must ‘Bring Something Back’—Here's What They Mean – Parade Star Trek: Discovery’s Captain Burnham Creates Dilemma For Star Trek: Starfleet Academy Star Trek returns to Top 10 charts on Friday the 13th (& Paul Giamatti seems to be why) New 88% RT Star Trek Show Gets Exciting Season 2 Update STAR TREK: STARFLEET ACADEMY Gives VOYAGER’s Doctor New Role – Nerdist Alex Kurtzman Learned to Put the Stars of ‘Starfleet Academy’ in Danger From an Unlikely Source Unannounced “Star Trek: United” A Star Trek Producer Has A Perfect Idea To Bring Back Captain Archer Trek series that never were, for one reason or another, [such as “Phase II”] ‘Star Trek Phase II’: The Lost ’70s Series That Shaped the Franchise | Woman’s World THEATRICAL MOTION PICTURES (in order of premiere) Star Trek: Generations (1994) Tom Hanks Nearly Changed the Best Star Trek Movie Ever Made Star Trek (2009) Starfleet Academy subtly pays homage to J.J. Abrams’ Star Trek (2009) Star Trek into Darkness (2013) Star Trek Into Darkness Director J.J. Abrams Has One Big Regret About The Sequel Karl Urban’s Script Critique Led To One Of Star Trek Into Darkness’ Funniest LinesTrek movies that never were, for one reason or another, [such as Tarantino’s movie] The Lost ‘Star Trek’ Starfleet Academy Movie: An Inside Look (Exclusive) | Woman’s World The Lost 1970s ‘Star Trek' Movie That Almost Changed Spock Forever | Woman’s World OTHER MEDIAStar Trek video games/board games Everything We Know About Star Trek: Across the Unknown – Trek Central NickALive!: Star Trek: Voyager – Across the Unknown | Personal Log: Tom Paris | English | Daedalic Entertainment Ezri Dax returns to Star Trek Online to face a Lovecraftian threat Star Trek toys/collectibles/other merchandise Nacelle Showcases STAR TREK Action Figure Paint Masters, Holodeck, TOS Bridge Playset, and More at Toy Fair 2026 – TrekCore.com Star Trek Comics/graphic novels/magazines After 37 Years, Star Trek Makes Its Biggest Starfleet Retcon Yet With the Borg NickALive!: Star Trek: Starfleet Academy–Lost Contact Trailer | IDWPublishing Ensign’s Log: Nyota Uhura shines on in STAR TREK: DEVIATIONS – THREADS OF DESTINY #1 REVIEW – Star Trek: Deviations – Threads of Destiny – Trek Central The Future of ‘Star Trek’ Comics Is Ready for a New Next Generation (Exclusive) IDW Launching Two New STAR TREK Comic Series in September, Additional CELEBRATIONS One-Shots, and More! – TrekCore.com MISCELLANEOUS Franchise-wide/Miscellaneous Star Trek: Everything We NOW Know About The Lost Era Star Trek: 10 Episodes That Are UNWATCHABLE Now 28 Memorable ‘Star Trek’ Crossovers Across 60 Years | Woman’s World ‘Star Trek Next Generation’ Cast Then and Now: 35 Years Later | Woman’s World 10 Worst Star Trek Ship Designs, Ranked ‘Star Trek: Starfleet Academy' wants you to flash the Vulcan salute at Pier 39 Some Star Trek Fans Complain About The Franchise's Direction, But I Need To Hit Back After Watching Final Frontier For The First Time | Cinemablend The Kelvin Timeline's Lasting Legacy: How Abrams’ Star Trek Trilogy Shaped the Franchise's Streaming Era – TREKNEWS.NET | Your daily dose of Star Trek news and opinion Convention news/fandom Star Trek celebrates 60 years with star-studded cruise – CBS News The Lost Story That United the Original ‘Star Trek’ and ‘Doctor Who’ | Woman’s World How ‘Star Trek' Fans Saved the Show With a Million Letters (EXCLUSIVE) | Woman’s World Actor Watch STAR TREK: VOYAGER's Captain Janeway Defends STARFLEET ACADEMY's Captain Ake From Online Trolls Beam Me Up, Sulu Directors on Star Trek’s Ongoing Cultural Relevance Leonard Nimoy | All Star Trek James Doohan Military Service: ‘Star Trek’ Scotty’s Secret D-Day Story | Woman’s WorldPassings ‘Star Trek' Actor John Wheeler Dead at 95 Main Mission, Part 2 Star Trek: Starfleet AcademySeason 1, Episode 8“The Life of the Stars”Written by Gaia Violo & Jane MaggsDirected by Andi Armaganian Our Town 2003 Broadway Production Paul Newman as Stage Manager – YouTube Time to refill the dilithium chamber and warp on out of here! End Of Show It’s about time to refill the dilithium chamber and get on out of here. Find Clinton at Comedy4Cast Find Chuck and Kreg at Technorama Podcast If you liked the show, please be sure to tell a friend about it. And subscribe, so you’ll never miss an episode. We’d love to hear from you. Follow us on BlueSky (@thetopicistrek), visit our Facebook page or call us at 816-TREKKER, that’s (816) 873-5537 Until next time, on behalf of my absent co-hosts, Chuck, Kreg and myself, and my special guest, Gary, I’m Clinton, thanking you for listening. And, as we always say here on “The Topic Is Trek” Don’t put on the red shirt! END RECORDING – HAILING FREQUENCIES CLOSED

Discover how to lose weight without Ozempic using 5 evidence-backed strategies. This episode breaks down why insulin resistance is the real driver of weight gain and how cutting processed foods, eating only when hungry, fasting, weight resistance training, and detoxification can help you lose weight naturally and sustain it long-term — no prescription required. FEATURED PRODUCT The Good Poops Protocol is designed to support the exact systems discussed in this episode — liver detoxification, gut health, and blood sugar regulation. 

We’re starting our read of Cavan Scott’s Path of Vengeance, the final novel in Phase II of the High Republic. We talk about ghosts, unraveling the Mother’s identity, and what Marda Ro has been up to (spoiler alert: it’s cult shit). For a list of Black-owned bookstores to order from, now and always, click here. […]

What if one of the most powerful tools for detoxification, brain health, hormone balance, and healthy aging was something you could grow in your kitchen? In this science-packed episode of The Girlfriend Doctor Podcast, Dr. Anna Cabeca sits down with renowned nutritional biochemist Dr. Jed W. Fahey — the pioneering researcher behind the discovery of the extraordinary chemoprotective power of broccoli sprouts. After 27 years at Johns Hopkins University School of Medicine, where he directed the Cullman Chemoprotection Center, Dr. Fahey explains why sulforaphane — derived from glucoraphanin found abundantly in broccoli sprouts — activates your body's own protective systems at the cellular level. Dr. Anna shares her personal clinical experiences using sulforaphane-rich compounds to support detoxification pathways, immune resilience, abnormal Pap smears, skin health, neurocognitive protection, and hormone balance — especially in midlife women. In this episode, you'll learn: What sulforaphane actually is (and why it matters) How it activates phase II detoxification pathways Why broccoli sprouts are more potent than mature broccoli Neuroprotective and brain benefits Research around skin and melanoma protection Dosage guidance for sprouts vs. supplements How to safely incorporate them into your daily routine This isn't about trendy superfoods. It's about turning on your body's built-in defense systems. Small daily choices. Powerful cellular protection.   Key Timestamps 00:01 – Welcome & why broccoli sprouts matter 03:14 – Broccoli sprouts vs. mature broccoli: what's the difference? 06:21 – What exactly is sulforaphane? 09:24 – Phase II detoxification explained simply 15:23 – Dr. Anna's powerful clinical case using sulforaphane 17:31 – Brain health & neurocognitive benefits 24:43 – How much should you take daily? 31:24 – Skin health & melanoma research 33:35 – Food vs. supplement: dosage considerations 42:13 – One big takeaway for healthy aging   Memorable Quotes "This isn't about complicated science. It's about small daily choices that protect your cells." "Sulforaphane switches on your body's own protective systems." "Broccoli sprouts are foundational — not optional — for longevity." "We want to help and do no harm." "You were made for vitality."   Connect With Our Guest Dr. Jed W. Fahey

On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Chief Policy Officer Michael Koplow and Distinguished RAND Israel Policy Chair Shira Efron. The trio discuss this week's summit meeting in Washington between President Trump and Prime Minister Netanyahu, the chances of negotiations with Iran actually succeeding, the likely gaps between the U.S. and Israel over any potential deal, the threat of a military attack if diplomacy fails, how Phase II in Gaza is going, the recent damaging steps taken by the Israeli government on the West Bank, and more.Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.

On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber and Israel Policy Forum Director of Strategic Initiatives and IPF Atid Shanie Reichman discuss the state of play in the Iran crisis, potential upcoming U.S.-Iran talks and the prospects for their success, Ran Gvili z”l's return home last week and the closure of the hostage saga, the real start of Phase II in the Gaza ceasefire and the mechanics behind it, Zohran Mamdani and the Jewish community one month in, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.

What will Phase II of Trump's plan for Gaza look like on the ground? Who's  in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing structure — Trump's “Board of Peace,” the Gaza Executive Committee, a Palestinian technocrat government, and an International Stability Force — and explain what will actually matter on the ground: money, security control, and whether Hamas truly disarms. They also assess Israel–U.S. friction, the odds of renewed fighting, what daily life in Gaza looks like right now, and how all of this collides with Israeli election politics.In this episode...- Understanding the Governance of Gaza- Who Holds Power in Gaza? Money, Security, and Accountability- Hamas After the War- Phase Two, the Yellow Line, and Israeli Withdrawal- The International Stability Force Explained- Life in Gaza Right Now- Gaza Meets Israeli Politics- The Bigger Regional PictureFrom the episode:This episode was sponsored by The Shalom Hartman Institute: Learn more about the Community Leadership Program at https://go.hartman.org.il/CLP-CMBMore Ark Media:Want to join Ark Media? Check out our careers page for new openings.Subscribe to Inside Call me BackListen to For Heaven's SakeListen to What's Your Number?Watch Call me Back on YouTubeNewsletters | Ark Media | Amit Segal | Nadav EyalInstagram | Ark Media | DanX | DanDan Senor & Saul Singer's book, The Genius of IsraelGet in touchCredits: Ilan Benatar, Adaam James Levin-Areddy, Brittany Cohen, Martin Huergo, Mariangeles Burgos, and Patricio Spadavecchia, Yuval Semo 

What will Phase II of Trump's plan for Gaza look like on the ground? Who's  in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing […]

Roche/Genentech announced on June 15–16, 2025 that prasinezumab — an anti-α-synuclein monoclonal antibody — will enter Phase III trials for early Parkinson's disease after mixed but encouraging Phase II signals.  In this episode (watch on YouTube) we explain the biology behind α-synuclein targeting, summarize the PASADENA and PADOVA findings (what was missed and what looked promising), discuss safety issues and trial design challenges, and speak with experts/patients about realistic timelines and hopes for disease-modifying therapies To follow trials like this and to have customized information and results delivered to you directly, consider signing up to try Turnto and the AI sidekick Turny. Sign up here and use the promo code PDEDUCATION for a 10% discount: https://www.turnto.ai/sidekick?fpr=pdeducation Help to support this channel and out efforts to educate the world about Parkinson's Disease and get access to personalized content: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join  https://www.patreon.com/pdeducation Please be sure to give support to our channel sponsors: Comfort Linen: https://comfortlinen.com/PARKINSONSDISEASEEDUCATION(15% off entire order when applying the code PARKINSONSDISEASEEDUCATION at checkout) Kizik Shoes: https://kizik.sjv.io/pdeducation Cure Hydration: https://lvnta.com/lv_XG06Rho8SSlXEq3qlV If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013 Medical Disclaimer All information, content, and material of this video is for informational purposes only and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Affiliate disclaimer: Keep in mind that links used for recommended products may earn me a commission when you make purchases. However, this does not impact what products I recommend. If I recommend a specific product it is because it has been vetted by myself or based on personal use. #parkinson #parkinsonsawareness #parkinsonsdisease #parkinsons #prasinezumab #monoclonalantibodies #alphasynuclein

Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson's disease and outlines Phase II plans for the company's lead asset HER-096.

Tinnitus isn't just a ringing in your ears — it can interfere with memory, mood, and sleep, affecting your overall well-being when left unmanaged A Phase II clinical trial found that low-intensity sound therapy (LINTS) can reduce tinnitus symptoms without blocking out real-world sounds, helping the brain tune out the ringing naturally Sound therapy works by helping your brain reclassify tinnitus as background noise, reducing its emotional and cognitive impact over time For best results, work with a professional — sound therapy is most effective when guided by a trained audiologist Supporting your body with antioxidant-rich foods, magnesium, deep sleep, and a low-stress lifestyle can also reduce tinnitus intensity and help protect your hearing

THIS VOYAGE, MARK A. ALTMAN (Pandora, The Librarians, 50 Year Mission), DAREN DOCHTERMAN (associate producer, STAR TREK: THE MOTION PICTURE) & ASHLEY E. MILLER (writer, Thor, X-Men: First Class) celebrate the 46th anniversary of STAR TREK: THE MOTION PICTURE as we are joined by associate producer JON POVILL, Epsilon 9 casualty MICHELE BILLY POVILL, publicist EDDIE EGAN, The Walking Dead showrunner and creative director SCOTT GIMPLE and Alien Boy himself, BILLY VAN ZADNT, whose been with the podcast every minute of her refitting. This is how we definite unwarranted! Join the Treksperts and special guests as we trace the development of Phase II's "In Thy Image" into the epic motion picture released December 7, 1979.**DON'T MISS THE TREKSPERTS AT GALAXYCON COLUMBUS 12/5 - 12/7 FOR MORE INFORMATION, GO TO GALAXYCON.COM ****TREKSPERTS+ SUBSCRIBERS NOW GET COMMERCIAL FREE EPISODES ONE WEEK EARLY! SUBSCRIBE TODAY AT TREKSPERTSPLUS.COM****Join us on our new INGLORIOUS TREKSPERTS DISCORD Channel at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/7kgmJSExeh⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rate and follow us on social media at:Blue Sky: @inglorioustrekspertsTwitter/X:@inglorioustrekFacebook:facebook.com/inglorioustrekspertsInstagram/Threads: @inglorioustrekspertsLearn all that is learnable about Star Trek in Mark A. Altman & Edward Gross' THE FIFTY-YEAR MISSION, available in hardcover, paperback, digital and audio from St. Maritn's Press. Follow Inglorious Treksperts at @inglorioustrek on Twitter, Facebook and at @inglorioustreksperts on Instagram and Blue Sky. And now follow the Treksperts Briefing Room at @trekspertsBR, an entirely separate Twitter & Instagram feed."Mark A. Altman is the world's foremost Trekspert" - Los Angeles Times

Our good friends, Mike and JT from Brew Crime, join us for November's unsolved crossover. Today, JT tells us about a terrifying six-year murder spree (1990-1996) targeted at least thirteen vulnerable elderly women in Richmond's West End, creating widespread panic. The case was officially pinned on one killer, but the narrative quickly fell apart: the series was split by a two-year hiatus and featured a pronounced shift from the stabbing homicides of six Black women to the homicides of seven White women. The case was hastily "closed" for the Phase II victims through the highly disputed confession of a diagnosed schizophrenic with zero forensic links to the crime scenes, leaving the initial wave of brutal stabbings completely unresolved. The official resolution is rooted in systemic failure and alleged racial bias, ensuring the actual killer, or killers, walked free. Source for the Episode Associated Press. (1996, April 25). Pattern Sought in Richmond Killings. The Roanoke Times. https://scholar.lib.vt.edu/VA-news/ROA-Times/issues/1996/rt9604/960425/04250042.htm Cases Solved Using Forensic Genetic Genealogy: How DNA Profiles Crack Cold Cases. (n.d.). Genomelink. Retrieved November 3, 2025, from https://genomelink.io/blog/cases-solved-using-forensic-genetic-genealogy-how-dna-profiles-crack-cold-cases Leslie Burchart. (n.d.). In Wikipedia. Retrieved November 3, 2025, from https://en.wikipedia.org/wiki/Leslie_Burchart Perpetrator typologies and behavioral patterns in strangulation homicides: A Smallest Space Analysis. (n.d.). PMC. Retrieved November 3, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12046104 The Golden Years Murders. (n.d.). In Wikipedia. Retrieved November 3, 2025, from https://en.wikipedia.org/wiki/Golden_Years_Murders https://richmondstandard.com/richmond/2025/02/26/richmond-city-council-honors-black-nine-guardians-of-justice/  Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on the Mark Levin Show, On Monday's Mark Levin Show, 7 million old hippies turned out in the Democrat-Marxist-Islamist No Kings mini-parades on Saturday? Well, 330 million Americans did not. The tea party movements had massive rallies, and it wasn't just one day. How is this President a king? He's working through the courts when he's blocked on improving America. For example, in a victory for America the 9th Circuit court ruled that the National Guard can be deployed in Portland. Also, Democrats turned a continuing resolution into a government shutdown blackmail threat to reverse provisions of the big, beautiful bill. Later, Marxist-Islamist Zohran Mamdani is pro-terrorism - from his associations with Imam Siraj Wahaj, his support for Hamas, his calls to globalize the Intifada, and his ties to the Qatar royal family. If people in NYC vote for Mamdani, they are voting for somebody who embraces terrorists, terrorist organizations, and hence, by implication, terrorism. Mamdani is no moderate, he's a grave threat to the people in New York City. Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Mass legal and illegal immigration without assimilation causes profound cultural and societal changes, leading to a dark period in Western societies where Marxist-Islamist ideology smothers Enlightenment values. You can see this in NYC where foreign-born voters overwhelmingly support socialist-Islamist immigrant candidate Zohran Mamdani in the mayoral race against Andrew Cuomo and Curtis Sliwa. The Democrat Party relies on Marxist-socialist beliefs for power, abandoning the American founding, Declaration, Constitution, separation of powers, and genuine elections, instead favoring unelected judges, bureaucracy, and massive government spending to control the people. Later, Zohran Mamdani got his butt kicked at the NYC debate. He's a sloganeer, which is typical of Marxists, but he won't be substantive at all. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On Tuesday's Mark Levin Show, Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Also, Democrats are keeping the government shutdown by continuing to block a non-controversial continuing resolution to try and blackmail Republicans to approve $1.5 trillion in additional spending. This will generate massive debt—similar to the phony Inflation Reduction Act—leading to inflation, higher prices for gasoline, food, mortgages, and credit cards, ultimately harming average citizens and future generations. Later, Zohran Mandami must be defeated in New York's upcoming mayoral race. He dodges questions on Hamas support; campaigns with Imam Siraj Wahaj, who served as a character witness for the 1993 World Trade Center bombing mastermind and called for jihad. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture China is now in talks again with the US, their plan has failed. Big Antimony refinery is being setup in Alaska, Trump is countering China every step of the way. Bessent warns the longer the shutdown goes it could hurt the economy, this is what the [CB] are trying to do. Investments are pouring into the US. Trump now has the [DS] where he wants them. They called in facist/Hitler and it has failed, he ushered in peace around the world and now when he has peace with Ukraine and Russia they will have a very difficult time pushing these names. The FBI has dismantled the largest human trafficking network. Trump is letting the people know that Phase II of the plan is now on track. Obama is struggling he looks defeated, by the time this is over he will try to escape to Kenya and the D party will cease to exist.   Economy (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); https://twitter.com/KobeissiLetter/status/1977907063893225928 New: Alaska Scores Big on Antimony Refinery  Antimony (Sb on the periodic table) is a strategic mineral with many applications. Shooters will recognize it, as it is frequently allied with lead to make a harder, more durable alloy for cast bullets. We should note that lead-antimony alloys have many other uses, from lead-acid batteries to sailboat keels. Antimony is used in other alloys as well, such as antifriction alloys, electric cable sheathing, and type metals for printing presses, which apparently are not completely extinct yet. It's also used in flame retardants, and - this is key - in semiconductors. It's also has applications in pharmaceuticals.  a key strategic mineral. Alaska has antimony. Now, in Alaska, a company called Nova Minerals, with a grant from the War Department, has a contract to build an antimony refinery at Port MacKenzie, west of Anchorage, to process ore from the Estelle gold mine in the West Susitna Mineral District. With Pentagon backing and a goal to begin delivering Alaska-sourced antimony into U.S. supply chains by 2027, Nova Minerals Ltd. has secured a 42.8-acre site at Port MacKenzie west of Anchorage for a refinery that would process antimony concentrates from its Estelle project and other sources."This is a defining moment for Nova Minerals and for U.S. critical mineral independence," Nova Minerals CEO Christopher Gerteisen said upon securing land use permits for the industrial site about four miles from a deepwater port in Southcentral Alaska.The refinery, to be developed by Nova subsidiary Alaska Range Resources (ARR), is part of a strategy to leverage the very high-grade antimony mineralization found on the company's Estelle project about 100 miles west of Port MacKenzie to establish a domestic supply of this metalloid critical to a wide range of military and commercial applications. Antimony is also found in Idaho and Montana. But a majority of antimony production comes from countries that are not particularly friendly to the United States: China, Russia, and Tajikistan, which, between them, account for almost 80 percent of global supply. Source: redstate.com Johnson Warns Current Government Shutdown Could Be Longest Ever House Speaker Mike Johnson (R-La.) said on Oct.